Title: LegoChem submits a registration statement 

Publication: E-News Today

Date: 02 April 2013

Summary

• LegoChem Bioscience submitted Securities Report to the Financial Service Commission on 26th.

• LegoChem applied for New Growth Engine Company special evaluation to Korea Exchange and passed the preliminary evaluation only with its technological advancement and growth potential, not profitability.

• LegoChem signed 7 licensing-out agreements (anticoagulant, antibiotics, ADC and anti-inflammatory drug) and is conducting two phase 2 clinical studies and two nonclinical studies for new drugs. Also, LegoChem is trying to expand a number of pipelines through joint research with Sanofi Aventis on oncology.

   

To view the full article (in Korean), click here ▶

About LegoChem Biosciences

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).